Werewolf Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$60.7M | -$73.6M | -$40.5M | -$56.1M | -$50.1M |
| Operating expenses | $60.7M | $75.5M | $60.4M | $72.5M | $50.1M |
| Cash from operations | -$60.3M | -$56.2M | -$32.6M | -$40.6M | -$42.9M |
| Capital expenditure | $0 | $254,000 | $769,000 | $3.6M | $498,000 |
| Free cash flow | -$60.3M | -$56.4M | -$33.4M | -$44.2M | -$43.4M |
| Total assets | $69.4M | $126.9M | $174.8M | $160.2M | $179.2M |
| Total liabilities | $44.6M | $53.5M | $63.5M | $37.9M | $26.5M |
Shares outstanding 48.6M · Free float 63.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.